|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-5-13
|
|
pubmed:abstractText |
The (111)In-capromab pendetide scan (ProstaScint; Cytogen Corp., Princeton NJ) is approved by the Food and Drug Administration to evaluate increasing prostate-specific antigen (PSA) levels after radical prostatectomy. This study evaluated the role of prostate bed (111)In-capromab pendetide scan findings to predict response to salvage radiotherapy (RT).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
358-61
|
|
pubmed:meshHeading |
pubmed-meshheading:18164863-Aged,
pubmed-meshheading:18164863-Antibodies, Monoclonal,
pubmed-meshheading:18164863-Follow-Up Studies,
pubmed-meshheading:18164863-Humans,
pubmed-meshheading:18164863-Indicators and Reagents,
pubmed-meshheading:18164863-Indium Radioisotopes,
pubmed-meshheading:18164863-Male,
pubmed-meshheading:18164863-Prostate-Specific Antigen,
pubmed-meshheading:18164863-Prostatectomy,
pubmed-meshheading:18164863-Prostatic Neoplasms,
pubmed-meshheading:18164863-Retrospective Studies,
pubmed-meshheading:18164863-Salvage Therapy,
pubmed-meshheading:18164863-Survival Rate
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
|
|
pubmed:affiliation |
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA. koont005@mc.duke.edu
|
|
pubmed:publicationType |
Journal Article
|
